Novo Cuts US Weight Loss Drug Prices
Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US…
Tag: Novo
Novo Cuts Outlook Once Again, Highlighting Obesity Struggles
Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new chief executive. Revenue will rise only as much…
Novo Nordisk Offers $9 Billion Unsolicited Bid for Obesity Drug Maker Metsera
Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for dominance in the weight-loss market.The…
Trump Vows Lower Ozempic Prices, Novo Nordisk Shares Dip
Since taking office in January, Trump has been striving to narrow the gap between US and foreign drug prices. Under its “most favoured nation” policy, the US government will require drugmakers to charge patients in…